Skip to main content
Signal8
Launch Terminal

Apnimed, Inc. (APMD)

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Apnimed, Inc. logo

Apnimed, Inc.

NASDAQ:APMDHealthcare
-5.42%$16.40
AH$16.97+3.48%vs close
Mkt Cap$682.74M
Float17.93M
O/S41.63M
Vol
$ Vol
RVOL
Inst Own0.0%
SI10.1%
Earnings
Dilution
Apnimed, Inc. logoNASDAQ:APMD$16.40-5.42%
Phase Distribution
13 lead-sponsored trials·1 active·12 completed
Phase 1/21
Phase 29
Phase 33
(6 more as collaborator)
Status Overview
Recruiting1
Completed12

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

    AD109, Placebo

    OSA

    Enrollment
    660
    Start
    Aug 2023
    Primary Completion
    May 2025
    Completion
    May 2025
    NCT05811247
  • Phase 3
    Completed

    Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

    AD109, Placebo

    OSA

    Enrollment
    646
    Start
    Sep 2023
    Primary Completion
    Mar 2025
    Completion
    Mar 2025
    NCT05813275
  • Phase 3
    Enrolling by invitation

    Continuation Protocol for Obstructive Sleep Apnea (OSA)

    Aroxybutynin and Atomoxetine

    OSA

    Enrollment
    1,280
    Start
    Jul 2024
    Primary Completion
    Jun 2026est.
    Completion
    Jun 2026est.
    NCT06566820
  • Phase 2
    Completed

    Trial of AD036 in Obstructive Sleep Apnea

    AD036 Dose 1, AD036 Dose 2

    Obstructive Sleep Apnea

    Enrollment
    140
    Start
    Mar 2019
    Primary Completion
    Oct 2019
    Completion
    Oct 2019
    NCT03845023
  • Phase 2
    Completed

    Crossover Trial of AD036 in Obstructive Sleep Apnea

    AD036, Atomoxetine

    Obstructive Sleep Apnea

    Enrollment
    62
    Start
    Jul 2020
    Primary Completion
    Dec 2020
    Completion
    Dec 2020
    NCT04445688
  • Phase 2
    Completed

    Crossover Trial of AD109 in Obstructive Sleep Apnea

    AD109, Atomoxetine

    Obstructive Sleep Apnea

    Enrollment
    60
    Start
    Oct 2020
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT04580394
  • Phase 2
    Completed

    AD109 Dose Finding in Mild to Moderate OSA

    AD109 dose1- A, AD109 dose2- B

    Obstructive Sleep Apnea

    Enrollment
    32
    Start
    Dec 2020
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT04631107
  • Phase 2
    Completed

    Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

    AD182, AD504

    Obstructive Sleep Apnea

    Enrollment
    15
    Start
    Dec 2020
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT04645524
  • Phase 2
    Completed

    Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

    AD113, Atomoxetine

    Obstructive Sleep Apnea, Hypertension

    Enrollment
    21
    Start
    Jul 2021
    Primary Completion
    Jan 2023
    Completion
    May 2023
    NCT04905979
  • Phase 2
    Completed

    Parallel Arm Trial of AD109 and AD504 In Patients With OSA

    AD109, AD504

    OSA - Obstructive Sleep Apnea

    Enrollment
    294
    Start
    Nov 2021
    Primary Completion
    Jul 2022
    Completion
    Aug 2022
    NCT05071612
  • Phase 2
    Completed

    AD816 Crossover Study

    Period A, Period B

    OSA, Obstructive Sleep Apnea

    Enrollment
    25
    Start
    Apr 2023
    Primary Completion
    Nov 2023
    Completion
    Nov 2023
    NCT05793684
  • Phase 2
    Completed

    Study That Tests AD109 in Patients Taking GLP-1 Drugs

    AD109

    OSA

    Enrollment
    40
    Start
    May 2024
    Primary Completion
    Dec 2024
    Completion
    Dec 2024
    NCT06400615
  • Phase 1/2
    Completed

    Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

    Dosing 1: Atomoxetine, AD313

    Obstructive Sleep Apnea

    Enrollment
    15
    Start
    Oct 2021
    Primary Completion
    Apr 2022
    Completion
    Apr 2022
    NCT05101122
Search ClinicalTrials.gov for “Apnimed”